Leading up to Christmas and per expectations, Cynata announced its clinical trial of CYP‑006TK in patients with diabetic foot ulcers (DFU) had commenced and is now open for patient enrolment.
Another, long-established company has been the poster child for stem cell therapy however, there’s several smaller and promising regenerative medicine companies that are doing things differently and making rapid progress. And this includes Cynata addressing the complexities and challenges of manufacturing MSCs at a commercial scale, producing essentially infinite quantities of consistent and potent MSCs from a single donor from a single blood donation.
As we experience the return of many freedoms across Victoria and NSW, many of us are busily scheduling in time with friends/family, eating out, hair and other appointments etc. Professor David Hunter and Dr Ross Macdonald are encouraging those suffering from OA to consider enrolling for the ongoing osteoarthritis clinical trial.
Cynata and Fujifilm have entered a new and exciting strategic partnership agreement which includes detailed and agreed core terms for Fujifilm to provide clinical and commercial manufacturing services for, and supply of its Cymerus MSC products. BioWorld covered this, and Cynata’s quarter of milestones in depth here (subscriber only content)
The paper, which summarises the results of studies led by Associate Professor James Chong (Westmead Institute for Medical Research, Sydney), validates the importance of Cymerus MSCs in treating serious and debilitating diseases and provides further recognition of Cynata’s advanced technology.